Research ArticleOMERACT 11

Current Status of Outcome Measure Development in Vasculitis

Peter A. Merkel, Sibel Z. Aydin, Maarten Boers, Christina Cornell, Haner Direskeneli, Don Gebhart, Gulen Hatemi, Raashid Luqmani, Eric L. Matteson, Nataliya Milman, Joanna Robson, Philip Seo and Gunnar Tomasson
The Journal of Rheumatology March 2014, 41 (3) 593-598; DOI: https://doi.org/10.3899/jrheum.131248

REFERENCES

  1. 1.↵
    1. Watts RA,
    2. Suppiah R,
    3. Merkel PA,
    4. Luqmani R
    . Systemic vasculitis—is it time to reclassify? Rheumatology 2011;50:643–5.
    OpenUrlFREE Full Text
  2. 2.↵
    1. Jennette JC,
    2. Falk RJ,
    3. Bacon PA,
    4. Basu N,
    5. Cid MC,
    6. Ferrario F,
    7. et al.
    2012 revised international Chapel Hill Consensus Conference nomenclature of vasculitides. Arthritis Rheum 2013;65:1–11.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Jayne D,
    2. Rasmussen N,
    3. Andrassy K,
    4. Bacon P,
    5. Tervaert JW,
    6. Dadoniené J,
    7. et al.
    A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003;349:36–44.
    OpenUrlCrossRefPubMed
  4. 4.↵
    Etanercept plus standard therapy for Wegener’s granulomatosis. N Engl J Med 2005;352:351–61.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. De Groot K,
    2. Rasmussen N,
    3. Bacon PA,
    4. Tervaert JW,
    5. Feighery C,
    6. Gregorini G,
    7. et al.
    Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005;52:2461–9.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Hiemstra TF,
    2. Walsh M,
    3. Mahr A,
    4. Savage CO,
    5. de Groot K,
    6. Harper L,
    7. et al.
    Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial. JAMA 2010;304:2381–8.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Jones RB,
    2. Tervaert JW,
    3. Hauser T,
    4. Luqmani R,
    5. Morgan MD,
    6. Peh CA,
    7. et al.
    Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010;363:211–20.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Stone JH,
    2. Merkel PA,
    3. Spiera R,
    4. Seo P,
    5. Langford CA,
    6. Hoffman GS,
    7. et al.
    Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010;363:221–32.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Hoffman GS,
    2. Cid MC,
    3. Hellmann DB,
    4. Guillevin L,
    5. Stone JH,
    6. Schousboe J,
    7. et al.
    A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum 2002;46:1309–18.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Hoffman GS,
    2. Cid MC,
    3. Rendt-Zagar KE,
    4. Merkel PA,
    5. Weyand CM,
    6. Stone JH,
    7. et al.
    Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med 2007;146:621–30.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Merkel PA,
    2. Seo P,
    3. Aries P,
    4. Neogi T,
    5. Villa-Forte A,
    6. Boers M,
    7. et al.
    Current status of outcome measures in vasculitis: focus on Wegener’s granulomatosis and microscopic polyangiitis. Report from OMERACT 7. J Rheumatol 2005;32:2488–95.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. Seo P,
    2. Luqmani RA,
    3. Flossmann O,
    4. Hellmich B,
    5. Herlyn K,
    6. Hoffman GS,
    7. et al.
    The future of damage assessment in vasculitis. J Rheumatol 2007;34:1357–71.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Merkel PA,
    2. Herlyn K,
    3. Mahr AD,
    4. Neogi T,
    5. Seo P,
    6. Walsh M,
    7. et al.
    Progress towards a core set of outcome measures in small-vessel vasculitis. Report from OMERACT 9. J Rheumatol 2009;36:2362–8.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    1. Direskeneli H,
    2. Aydin SZ,
    3. Kermani TA,
    4. Matteson EL,
    5. Boers M,
    6. Herlyn K,
    7. et al.
    Development of outcome measures for large-vessel vasculitis for use in clinical trials: opportunities, challenges, and research agenda. J Rheumatol 2011;38:1471–9.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    1. Merkel PA,
    2. Aydin SZ,
    3. Boers M,
    4. Direskeneli H,
    5. Herlyn K,
    6. Seo P,
    7. et al.
    The OMERACT core set of outcome measures for use in clinical trials of ANCA-associated vasculitis. J Rheumatol 2011;38:1480–6.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    1. Herlyn K,
    2. Hellmich B,
    3. Seo P,
    4. Merkel PA
    . Patient-reported outcome assessment in vasculitis may provide important data and a unique perspective. Arthritis Care Res 2010;62:1639–45.
    OpenUrlCrossRef
  17. 17.↵
    1. Seo P,
    2. Jayne D,
    3. Luqmani R,
    4. Merkel PA
    . Assessment of damage in vasculitis: expert ratings of damage. Rheumatology 2009;48:823–7.
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    1. Walsh M,
    2. Mukhtyar C,
    3. Mahr A,
    4. Herlyn K,
    5. Luqmani R,
    6. Merkel PA,
    7. et al.
    Health-related quality of life in patients with newly diagnosed antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res 2011;63:1055–61.
    OpenUrlCrossRef
  19. 19.↵
    1. Tomasson G,
    2. Boers M,
    3. Walsh M,
    4. LaValley M,
    5. Cuthbertson D,
    6. Carette S,
    7. et al.
    Assessment of health-related quality of life as an outcome measure in granulomatosis with polyangiitis (Wegener’s). Arthritis Care Res 2012;64:273–9.
    OpenUrlCrossRef
  20. 20.↵
    1. Exley AR,
    2. Bacon PA,
    3. Luqmani RA,
    4. Kitas GD,
    5. Gordon C,
    6. Savage CO,
    7. et al.
    Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum 1997;40:371–80.
    OpenUrlCrossRefPubMed
  21. 21.↵
    1. Stone JH,
    2. Hoffman GS,
    3. Merkel PA,
    4. Min YI,
    5. Uhlfelder ML,
    6. Hellmann DB,
    7. et al.
    A disease-specific activity index for Wegener’s granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS). Arthritis Rheum 2001;44:912–20.
    OpenUrlCrossRefPubMed
  22. 22.↵
    1. Mukhtyar C,
    2. Lee R,
    3. Brown D,
    4. Carruthers D,
    5. Dasgupta B,
    6. Dubey S,
    7. et al.
    Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis 2009;68:1827–32.
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    1. Bruyère SM,
    2. Van Looy SA,
    3. Peterson DB
    . The International Classification of Functioning, Disability and Health: Contemporary Literature Overview. Rehabil Psychol 2005;50:113–21.
    OpenUrlCrossRef
  24. 24.↵
    1. Stucki G,
    2. Boonen A,
    3. Tugwell P,
    4. Cieza A,
    5. Boers M
    . The World Health Organisation International Classification of Functioning, Disability and Health: a conceptual model and interface for the OMERACT process. J Rheumatol 2007;34:600–6.
    OpenUrlAbstract/FREE Full Text
  25. 25.↵
    1. Hatemi G,
    2. Merkel PA,
    3. Hamuryudan V,
    4. Boers M,
    5. Direskeneli H,
    6. Aydin SZ,
    7. et al.
    Outcome measures used in clinical trials for Behçet’s syndrome: a systematic review. J Rheumatol 2014;41:599–612.
    OpenUrlAbstract/FREE Full Text
  26. 26.↵
    1. Boers M,
    2. Kirwan J
    . How to choose core outcome sets for clinical trials: OMERACT 11 approves Filter 2.0. J Rheumatol 2014 (in press).
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

 Request Permissions

Bookmark this article

Jump to section

Keywords

OUTCOMES
VASCULITIS
ASSESSMENT

Keywords